Aberrant expression of the microtubule-associated protein tau is an independent prognostic feature in prostate cancer

• Published in: BMC cancer Vol. 19; no. 1; p. 193
• Main Authors: Schroeder, Cornelia, Grell, Jan, Hube-Magg, Claudia, Kluth, Martina, Lang, Dagmar, Simon, Ronald, Höflmayer, Doris, Minner, Sarah, Burandt, Eike, Clauditz, Till S, Büscheck, Franziska, Jacobsen, Frank, Huland, Hartwig, Graefen, Markus, Schlomm, Thorsten, Sauter, Guido, Steurer, Stefan
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 01.03.2019; BioMed Central; BMC
• Subjects: Biochemistry; Cancer research; Cancer treatment; Deletion; EDTA; ERG; Fluorescence; Gene expression; Genetic aspects; Immunohistochemistry; MAPT; Microtubules; Prognosis; Prostate cancer; PTEN; Tau; Tumors; Deletion; PTEN; Tau; ERG; MAPT; Prostate cancer
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-019-5390-1

Microtubule-associated protein Tau (MAPT) overexpression has been linked to poor prognosis and decreased response to taxane-based therapies in several cancer types, but its relevance in prostate cancer is unknown. In this study, MAPT expression was analyzed by immunohistochemistry on a tissue microarray containing 17,747 prostate cancers. MAPT was absent in normal prostate epithelial cells but detectable in 1004 (8.2%) of 12,313 interpretable cancers. Its expression was associated with advanced tumor stage, high Gleason grade, positive lymph nodes, and early biochemical recurrence (p < 0.0001 each). For example, MAPT was found in 3.6% of 2072 Gleason ≤3 + 3 cancers but in 14.4% of 704 Gleason ≥4 + 4 cancers. High-level MAPT staining was also linked to TMPRSS2:ERG fusions (p < 0.0001). MAPT staining was seen in 15.2 and 16% of cancers with TMPRSS2:ERG fusion detected by immunohistochemistry and fluorescence in-situ hybridization, but in only 3.5 and 3.9% of cancers without ERG staining or ERG rearrangements. Moreover, an association was found between MAPT expression and PTEN deletions, with 19% MAPT positivity in 948 PTEN deleted cancers but only 7% MAPT positivity in 3895 tumors with normal PTEN copy numbers (p < 0.0001). Multivariate analysis revealed that the prognostic value of MAPT was independent from established parameters. Conventional large section analyses showed intratumoral MAPT heterogeneity in all three analyzed cancers. The results of our study identify MAPT, as a moderate prognostic marker in prostate cancer, whose clinical impact, however, may be limited due to the rarity and heterogeneity of its expression.